• Overall response rate. [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
  

Drug: Marqibo® (vincristine sulfate liposomes injection)
Subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.

Inclusion Criteria:

• Uveal melanoma with histologic or cytologic confirmation of metastatic disease.
• One unidimensionally measurable lesion. If this is a cutaneous lesion it must be at least 10 mm by caliper measure. If it is a visceral or nodal or soft tissue lesion, it must be >20 mm with conventional techniques or >10 mm with spiral CT scan. Bone lesions are not considered measurable.
• Previously untreated or may have received one prior systemic chemotherapy. Prior treatment with immunotherapy or vaccine is allowed provided there is documentation of disease progression. Prior treatment with hepatic arterial chemotherapy infusion/perfusion or chemoembolization of liver metastasis is allowed as long as there is extrahepatic disease or progression of the liver metastasis after regional therapy.
• Adequate liver, renal, and bone marrow function.
• Zubrod performance status of 0-2.
• Age > 18 years old.
• Sign an informed consent form.

Exclusion Criteria:

• Radiotherapy, chemotherapy, immunotherapy, vaccine treatment and/or alternative anticancer treatments (including investigational drugs) within 3 weeks prior to study enrollment.
• Hepatic chemoembolization within 4 weeks prior to study enrollment.
• Major surgery within 4 weeks of enrollment.
• Advanced symptomatic central nervous system (CNS) involvement by melanoma and those on phenytoin or requiring steroids for brain metastases, spinal cord compression, or meningeal "carcinomatosis".
• History of neurological disorders unrelated to chemotherapy (including familial neurological diseases and acquired demyelinating disorders).
• Grade 3 or greater sensory, motor or autonomic neuropathy at screening from any cause.
• Receiving treatment with drugs known to inhibit or induce hepatic drug metabolism by cytochrome P450-3A4 isoenzymes and/or P-glycoprotein within 1 week of study enrollment.